Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data
05:07am, Thursday, 17'th Jun 2021
German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ: BNTX), which along with its U.S. partner Pfizer, Inc. (NYSE: PFE), has
CureVac stock drops more than 50% on news trial COVID vaccine 47% effective
05:10pm, Wednesday, 16'th Jun 2021
Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.
CureVac's COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech
05:07pm, Wednesday, 16'th Jun 2021
CureVac's stock tanked after the announcement. The German biotech blamed variants in a press release.
CureVac: The Moment Of Truth Is Delayed Until August
05:34am, Monday, 14'th Jun 2021
CVAC's COVID-19 vaccine may not be reviewed by regulatory authorities until August.
RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday
02:41pm, Tuesday, 08'th Jun 2021
The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.
Could CureVac Be a Millionaire-Maker Stock?
08:10am, Tuesday, 08'th Jun 2021
This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in.
7 Best Vaccine Stocks for Their Pipeline Potential
01:45pm, Thursday, 03'rd Jun 2021
These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first o
Top COVID-19 Vaccine Stories of May Put Biotech ETFs in Focus
04:32pm, Tuesday, 01'st Jun 2021
Let's take a look at some top coronavirus vaccine stories of May and the possible impact they can have on biotech ETFs.
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
08:11am, Tuesday, 01'st Jun 2021
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data. The company said an independent
CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine
06:02pm, Monday, 31'st May 2021
CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.
Moderna: Stuck Between CureVac And A Hard Place
03:49am, Friday, 28'th May 2021
Moderna: Stuck Between CureVac And A Hard Place
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
03:47pm, Thursday, 27'th May 2021
Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
CureVac's Covid-19 Vaccine Has Important Role to Play in Fighting Variants, CEO Says
02:17pm, Wednesday, 26'th May 2021
The European regulator started a rolling review of the shot in February based on preliminary results from laboratory studies and early clinical studies in adults.
CureVac's COVID vaccine has important role to play in fighting variants, CEO says
10:17am, Wednesday, 26'th May 2021
CureVac's CEO said the company's experimental COVID-19 vaccine can still play an important role in the pandemic fight given the “rapid spread” of concerning variants.
Two COVID-19 vaccine makers in the news: CureVac and Moderna expanding production
10:24am, Monday, 24'th May 2021
With COVID-19 vaccines still scarce around the world, companies are announcing plans to expand production so as to speed up vaccine distribution worldwide. CuraVac N.V.
